Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1α expression in peripheral blood mononuclear cells

Jiang,Ya; Wang,Lin

doi:10.3892/mmr.2015.4494

Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1α expression in peripheral blood mononuclear cells

Authors:
- Ya Jiang
- Lin Wang
View Affiliations

Affiliations: Department of Orthopedics, The Third People's Hospital of Hefei, Hefei, Anhui 230022, P.R. China, Department of Orthopedics, The Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241002, P.R. China
Published online on: November 2, 2015 https://doi.org/10.3892/mmr.2015.4494
Pages: 35-40
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was performed to investigate the molecular mechanism of ankylosing spondylitis (AS). The interaction between micro (mi)RNA‑130a and its target tumor necrosis factor (TNF)‑1α and histone deactylase (HDAC)3 was assessed in peripheral blood mononuclear cells (PBMCs) from AS patients. Increased HDAC3 and decreased miRNA‑130a levels were observed in PBMCs from AS patients. HDAC3 knockdown or HDAC3 inhibition promoted the expression of miRNA‑130a, and HDAC3 was recruited to the promoter region of the gene encoding miRNA‑130a in PBMCs. In addition, miR‑130a overexpression led to a decrease, whereas miR‑130a inhibition led to an increase of TNF‑1α expression in PBMCs. Furthermore, HDAC3 knockdown or HDAC3 inhibition was associated with simultaneous upregulation of the expression of miR‑130a and downregulation of the expression of TNF‑1α in PBMCs. These results indicated that HDAC3 was involved in the regulation of the underlying molecular mechanism of AS by forming a negative feedback loop with miR-130a and enhancement of TNF-1α expression.

View Figures

View References

1	Kim N, Sun HY, Youn MY and Yoo JY: IL-1β-specific recruitment of GCN5 histone acetyltransferase induces the release of PAF1 from chromatin for the de-repression of inflammatory response genes. Nucleic Acids Res. 41:4495–4506. 2013. View Article : Google Scholar : PubMed/NCBI
2	Grabiec AM, Tak PP and Reedquist KA: Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: Should we keep our HATs on? Arthritis Res Ther. 10:2262008. View Article : Google Scholar : PubMed/NCBI
3	Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R, Zhang Y, Rembold M, Gaisberger M, Hartl A, et al: Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol. 185:3489–3497. 2010. View Article : Google Scholar : PubMed/NCBI
4	Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, Miconnet I, et al: Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood. 117:1205–1217. 2011. View Article : Google Scholar
5	Katto J, Engel N, Abbas W, Herbein G and Mahlknecht U: Transcription factor NFkB regulates the expression of the histone deacetylase SIRT1. Clin Epigenetics. 5:112013. View Article : Google Scholar
6	Blanchard F and Chipoy C: Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Discov Today. 10:197–204. 2005. View Article : Google Scholar : PubMed/NCBI
7	Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT and Kim DY: Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy. 35:89–96. 2005. View Article : Google Scholar : PubMed/NCBI
8	Toussirot E, Wendling D and Herbein G: CIC-1431: Biological treatments given in patients with rheumatoid arthritis or ankylosing spondylitis modify HAT/HDAC (histone acetyl-transferase/histone deacetylase) balance. Joint Bone Spine. 81:544–545. 2014. View Article : Google Scholar : PubMed/NCBI
9	Gillespie J, Savic S, Wong C, Hempshall A, Inman M, Emery P, Grigg R and McDermott MF: Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum. 64:418–422. 2012. View Article : Google Scholar
10	Strietholt S, Maurer B, Peters MA, Pap T and Gay S: Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther. 10:2192008. View Article : Google Scholar : PubMed/NCBI
11	Yang CR, Shih KS, Liou JP, Wu YW, Hsieh IN, Lee HY, Lin TC and Wang JH: Denbinobin upregulates miR-146a expression and attenuates IL-1β-induced upregulation of ICAM-1 and VCAM-1 expressions in osteoarthritis fibroblast-like synoviocytes. J Mol Med (Berl). 2014.Epub ahead of print. View Article : Google Scholar
12	Lu MC, Yu CL, Chen HC, Yu HC, Huang HB and Lai NS: Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production. Clin Exp Immunol. 177:641–651. 2014. View Article : Google Scholar : PubMed/NCBI
13	Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Minisola G, et al: miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol. 71:206–211. 2010. View Article : Google Scholar
14	Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH and Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 10:R1012008. View Article : Google Scholar : PubMed/NCBI
15	Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y, Liang D, He D, Wang H, Liu W, et al: The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat Med. 18:1077–1086. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lai NS, Yu HC, Chen HC, Yu CL, Huang HB and Lu MC: Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis. Clin Exp Immunol. 173:47–57. 2013. View Article : Google Scholar : PubMed/NCBI
17	Meng S, Cao J, Zhang X, Fan Y, Fang L, Wang C, Lv Z, Fu D and Li Y: Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3. PloS One. 8:e686112013. View Article : Google Scholar : PubMed/NCBI
18	Li S, Duan X, Li Y, Liu B, McGilvray I and Chen L: MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat. 21:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
19	Osbourne A, Calway T, Broman M, McSharry S, Earley J and Kim GH: Downregulation of connexin43 by microRNA-130a in cardiomyocytes results in cardiac arrhythmias. J Mol Cell Cardiol. 74:53–63. 2014. View Article : Google Scholar : PubMed/NCBI
20	Kim GH, Samant SA, Earley JU and Svensson EC: Translational control of FOG-2 expression in cardiomyocytes by microRNA-130a. PloS One. 4:e61612009. View Article : Google Scholar : PubMed/NCBI
21	Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E and Tao J: Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 31:3002–3008. 2012. View Article : Google Scholar
22	Kim Y, Kim H, Park H, Park D, Lee H, Lee YS, Choe J, Kim YM and Jeoung D: miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem. 289:28019–28039. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhang J, Kalkum M, Chait BT and Roeder RG: The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell. 9:611–623. 2002. View Article : Google Scholar : PubMed/NCBI
24	Bendinelli P, Matteucci E, Maroni P and Desiderio MA: NF-kappaB activation, dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells. Mol Cancer Res. 7:1328–1341. 2009. View Article : Google Scholar : PubMed/NCBI
25	Mahlknecht U, Will J, Varin A, Hoelzer D and Herbein G: Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol. 173:3979–3990. 2004. View Article : Google Scholar : PubMed/NCBI
26	Han KA, Kang HS, Lee JW, Yoo L, Im E, Hong A, Lee YJ, Shin WH and Chung KC: Histone deacetylase 3 Promotes RCAN1 Stability and nuclear translocation. PloS One. 9:e1054162014. View Article : Google Scholar : PubMed/NCBI
27	Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, Manganelli S and Galeazzi M: Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. 2014:8629692014.
28	Fenix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, Puigventós-Latorre F, Borrero-Rubio JM and López-Vallejo JF: Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther. 38:286–293. 2013. View Article : Google Scholar : PubMed/NCBI
29	Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L and Scarpa R: Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 33:833–839. 2014.